MedWatch

A part of Watch Media

Siemens Healthineers upgrades mid-term guidance

Germany-based Siemens Healthineers is now expecting revenue growth of 6-8 percent in the period 2023-2025, up from its prior 5-percent estimate. Morever, the projection for earnings per share in this period is also raised, going from 10 percent to 15 percent.

Photo: Daniel Karmann/AP/Ritzau Scanpix
by marketwire, translated by daniel pedersen

Siemens Healthineers, which sells products and solutions for the prevention, diagnosing, treatment and monitoring of diseases, has upgraded its mid-term guidance, Bloomberg News reports ahead of the company's capital markets day, referring to a press release.

Following the news, Siemens Healthineers' stock price went up 3.5 percent, trading at EUR 62.52.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

Foto: BENOIT TESSIER/REUTERS / X07241

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

  1. Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
  2. Novo Holdings portfolio company sold to US buyer
  3. Life science firms are planning USD 6.3bn construction spree in Denmark
  4. Lundbeck Foundation brings in experienced player to implement investment strategy
  5. Fujifilm invests USD 1.5bn in Danish factory
  6. Sanofi reduces US insulin prices for the uninsured
  7. Janssen awarded breakthrough therapy designation for Genmab bone marrow cancer drug
  8. Leo Pharma eczema treatment recommended in two UK countries
  9. Overview: Pharma giants and Bavarian Nordic fight over billion-dollar vaccine market
  10. Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
  11. Eargo raises USD 100m from investment firm
  12. US authorities expand monkeypox vaccine plan
  13. Stallergenes slapped with injunction
  14. EMA starts assessment of Bavarian Nordic's monkeypox vaccine
  15. Leo Pharma appoints experienced Swedish national to board

See all

Job

See all jobs

See all jobs